Stock Events

Stock Events

CorMedix

€6.1

0

-€0.1-1.61% Friday 18:47

Statistics

Day High

6.21

Day Low

6.1

52W High

13.6

52W Low

5.1

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7MayExpected

Q4 2025

Next

0.14

0.33

0.51

0.7

Expected EPS

0.3813235504

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 19KA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that competes with CorMedix in the development of drugs for infectious diseases, including those targeted by CorMedix's lead product, DefenCath.

Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals that directly compete with CorMedix's portfolio, especially in the antimicrobial space.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment, competes in the development and marketing of products that could be used in similar indications as CorMedix's, including infection prevention.

Abbott Laboratories

Abbott Laboratories offers a wide range of healthcare products that compete with CorMedix, particularly in the area of medical devices and diagnostics for infectious diseases.

Amgen competes with CorMedix in the biopharmaceutical field, focusing on innovative treatments that could overlap with CorMedix's market, especially in the area of infection control.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas that compete with CorMedix, particularly in the treatment of infectious diseases.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in the discovery and development of drugs in areas that could compete with CorMedix, including therapies for preventing and treating infections.

Novartis AG competes with CorMedix in the global healthcare market, particularly in the development and marketing of products for the treatment of various diseases, including those targeted by CorMedix.

AstraZeneca is a global, science-led biopharmaceutical business that competes with CorMedix in the development and commercialization of medicines for various diseases, including infections.

Sanofi is a global healthcare leader that competes with CorMedix in the areas of pharmaceuticals, including the development of treatments for infections similar to those targeted by CorMedix.

About

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Show more...

CEO

Mr. Joseph Todisco MBA

Employees

64

Country

United States

ISIN

US21900C3088

Listings

0 Comments

Share your thoughts

FAQ

What is CorMedix stock price today?▼

The current price of 19KA.STU is €6.1 EUR — it has decreased by -1.61% in the past 24 hours. Watch CorMedix stock price performance more closely on the chart.

What is CorMedix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange CorMedix stocks are traded under the ticker 19KA.STU.

Is CorMedix stock price growing?▼

19KA.STU stock has risen by +0.83% compared to the previous week, the month change is a +8.93% rise, over the last year CorMedix has showed a +0.83% increase.

When is the next CorMedix earnings date?▼

CorMedix is going to release the next earnings report on May 07, 2026.

What were CorMedix earnings last quarter?▼

19KA.STU earnings for the last quarter are 0.14 EUR per share, whereas the estimation was 0.7 EUR resulting in a -80.4% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does CorMedix have?▼

As of April 11, 2026, the company has 64 employees.

In which sector is CorMedix located?▼

CorMedix operates in the Health & Wellness sector.

When did CorMedix complete a stock split?▼

CorMedix has not had any recent stock splits.

Where is CorMedix headquartered?▼

CorMedix is headquartered in Parsippany, United States.